Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 21, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 189,775,040 shares of common stock were entitled to vote as of March 25, 2024, the record date for the Annual Meeting. There were 162,989,650 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 9, 2024 (the “Proxy Statement”). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.
Proposal 1: Election of Directors
|
|
|
|
|
|
|
| Directors Elected |
|
Vote For |
|
Withheld |
|
Broker
Non-Votes |
| Elizabeth McKee Anderson |
|
143,725,729 |
|
9,003,309 |
|
10,260,612 |
| Barbara W. Bodem |
|
152,126,450 |
|
602,588 |
|
10,260,612 |
| Athena Countouriotis, M.D. |
|
152,107,502 |
|
621,536 |
|
10,260,612 |
| Willard Dere, M.D. |
|
147,153,181 |
|
5,575,857 |
|
10,260,612 |
| Mark J. Enyedy |
|
152,125,947 |
|
603,091 |
|
10,260,612 |
| Alexander Hardy |
|
151,780,693 |
|
948,345 |
|
10,260,612 |
| Elaine J. Heron, Ph.D. |
|
144,192,766 |
|
8,536,272 |
|
10,260,612 |
| Maykin Ho, Ph.D. |
|
143,813,807 |
|
8,915,231 |
|
10,260,612 |
| Robert J. Hombach |
|
149,094,947 |
|
3,634,091 |
|
10,260,612 |
| Richard A. Meier |
|
146,622,137 |
|
6,106,901 |
|
10,260,612 |
| David E.I. Pyott, M.D. (Hon.) |
|
146,332,496 |
|
6,396,542 |
|
10,260,612 |
Based on the votes set forth above, BioMarin’s stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm
The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2024, as set forth in the Proxy Statement, received the following votes:
|
|
|
|
|
| For |
|
Against |
|
Abstain |
| 156,548,552 |
|
6,404,458 |
|
36,640 |
Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2024.
Proposal 3: Advisory Vote on the Compensation of Named Executive Officers
The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes:
|
|
|
|
|
|
|
| For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
| 141,887,490 |
|
10,757,670 |
|
83,878 |
|
10,260,612 |
Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.
